Advances in MAPK biology are prompting the development of novel pan‑RAF, RAS and combination therapies to address the unmet needs of NRAS‑mutant and NF1‑loss melanoma.
Advances in MAPK biology are prompting the development of novel pan‑RAF, RAS and combination therapies to address the unmet needs of NRAS‑mutant and NF1‑loss melanoma.